Ipratropium vs Oxitropium bromide (Ba253BINEB)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Ipratropium

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT06074185 · Phase 2 · completed

The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.

No aligned efficacy figure on record for this race.

Oxitropium bromide (Ba253BINEB)

Developed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT02182661 · Phase 3 · completed

The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIpratropiumOxitropium bromide (Ba253BINEB)
Severe exacerbations, annualised rate—Not reported—Not posted · NCT02182661
Trough FEV1, change—Not reported—Not posted · NCT02182661
ACQ-5, change—Not reported—Not posted · NCT02182661
OCS dose reduction—Not reported—Not posted · NCT02182661

Severe exacerbations, annualised rate

Ipratropium
—Not reported
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661

Trough FEV1, change

Ipratropium
—Not reported
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661

ACQ-5, change

Ipratropium
—Not reported
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661

OCS dose reduction

Ipratropium
—Not reported
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Oxitropium bromide (Ba253BINEB): no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ipratropium: 3 of 4 rows · Oxitropium bromide (Ba253BINEB): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIpratropium
Dropout rate
—a
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
5.6%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT06074185 · Phase 2 · combination
show 4 more results
—
NCT04617015 · Phase 1 · registry result, not featured evidence
—Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—
NCT00583778 · Phase na · registry result, not featured evidence · combination
Serious AEs
0%a
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
a
upper respiratory infection 13.3%
dyspnea 6.7%
right foot fracture 6.7%
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
dyspnea 11.8%
cough 5.9%
pneumonia 5.9%
NCT00521222 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ipratropium

PROMIS Asthma Impact Scale 22.5 score @ 1wk
absolute value · score
No placebo or comparator arm
NCT06074185 · Phase 2 · combination
FEV1 10.8% (n=39)
percent change · % of baseline
No placebo or comparator arm
NCT04617015 · Phase 1 · registry result, not featured evidence
show 1 more result
8.9% (n=32)
NCT04617015 · Phase 1 · registry result, not featured evidence
Morning PEF Change L/Min -15.7 vs -5.6 Fluticasone HFA L/min @ 16wk
absolute change · L/min
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
8.4 vs -5.6 Fluticasone HFA L/min @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 -0.03 vs -0.12 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.08 vs -0.12 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Post-BD FEV1 Change 0.02 vs -0.11 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.07 vs -0.11 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1% Predicted -1% (n=15) vs -3.8% (n=13) Fluticasone HFA @ 16wk
absolute change · percentage points
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-2.5% (n=17) vs -3.8% (n=13) Fluticasone HFA @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Asthma Symptom 0.3 vs 0.4 Fluticasone HFA score @ 16wk
absolute change · score
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-1.2 vs 0.4 Fluticasone HFA score @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 47.5% (n=141) vs 52.5% (n=141) Levalbuterol @ 0wk
responder rate · % of participants
NCT00583778 · Phase na · registry result, not featured evidence · combination · converted to % from 67 Participants as posted
FEV1 Percent Predicted 47% (n=67) vs 45% (n=74) Levalbuterol @ 0wk
absolute change · percentage points
NCT00583778 · Phase na · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ipratropium's landscape · Oxitropium bromide (Ba253BINEB)'s landscape